
With the increased use of germline multigene panel testing for assessing inherited cancer risk, little is known about the acceptance of these tests—or the fear of them—by patients of ethnically diverse and economically disadvantaged groups who are known or possible carriers of mutations in cancer-related genes. A new study conducted at multiple academic sites in California reported broad approval of the tests by patients.
Like
Save
Share